Patents by Inventor Sarah Moreno

Sarah Moreno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF
    Publication number: 20210379031
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 9, 2021
    Applicant: Genzyme Corporation
    Inventors: Nikolai Bukanov, Sarah Moreno, Timothy E. Weeden
  • Biomarker of polycystic kidney disease and uses thereof
    Patent number: 11116755
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 14, 2021
    Assignee: Genzyme Corporation
    Inventors: Sarah Moreno, Nikolai Bukanov, Timothy E. Weeden
  • Biomarkers of polycystic kidney disease and uses thereof
    Patent number: 10871495
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of one or more markers selected from the group of Proliferating Cell Nuclear Antigen (PCNA), cyclin D1, cyclin D3, MAPKERK kinase 1 (MEK), ribosomal protein S6 (S6), phosphorylated ribosomal protein S6 (pS6), extracellular signal-regulated kinase (ERK), phosphorylated extracellular signal-regulated kinase (pERK), protein kinase B (Akt), phosphorylated protein kinase B (pAkt), caspase-2, total S6, and retinoblastoma binding protein (RBBP). Also provided are kits that include at least three antibodies that specifically bind to one or more of these markers.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: December 22, 2020
    Assignee: Genzyme Corporation
    Inventors: Oxana Beskrovnaya, Nikolai Bukanov, Sarah Moreno
  • BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF
    Publication number: 20180338961
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.
    Type: Application
    Filed: November 15, 2016
    Publication date: November 29, 2018
    Inventors: Nikolai Bukanov, Sarah Moreno, Timothy E. Weeden
  • BIOMARKERS OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF
    Publication number: 20170227551
    Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of one or more markers selected from the group of Proliferating Cell Nuclear Antigen (PCNA), cyclin D1, cyclin D3, MAPKERK kinase 1 (MEK), ribosomal protein S6 (S6), phosphorylated ribosomal protein S6 (pS6), extracellular signal-regulated kinase (ERK), phosphorylated extracellular signal-regulated kinase (pERK), protein kinase B (Akt), phosphorylated protein kinase B (pAkt), caspase-2, total S6, and retinoblastoma binding protein (RBBP). Also provided are kits that include at least three antibodies that specifically bind to one or more of these markers.
    Type: Application
    Filed: August 3, 2015
    Publication date: August 10, 2017
    Applicant: Genzyme Corporation
    Inventors: Oxana Beskrovnaya, Nikolai Bukanov, Sarah Moreno